Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Interest Expenses (2017 - 2022)

Sutro Biopharma (STRO) has disclosed Interest Expenses for 6 consecutive years, with $2.8 million as the latest value for Q3 2022.

  • Quarterly Interest Expenses rose 240.0% to $2.8 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Jun 2023, up 3.91% year-over-year, with the annual reading at $3.1 million for FY2021, 23.06% down from the prior year.
  • Interest Expenses hit $2.8 million in Q3 2022 for Sutro Biopharma, up from $594000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.0 million in Q2 2020 to a low of -$2.3 million in Q4 2020.
  • Historically, Interest Expenses has averaged $805947.4 across 5 years, with a median of $820000.0 in 2021.
  • Biggest five-year swings in Interest Expenses: soared 343.0% in 2019 and later tumbled 375.52% in 2020.
  • Year by year, Interest Expenses stood at -$649000.0 in 2018, then soared by 225.89% to $817000.0 in 2019, then tumbled by 375.52% to -$2.3 million in 2020, then skyrocketed by 127.19% to $612000.0 in 2021, then skyrocketed by 355.56% to $2.8 million in 2022.
  • Business Quant data shows Interest Expenses for STRO at $2.8 million in Q3 2022, $594000.0 in Q2 2022, and $657000.0 in Q1 2022.